At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
Vorinostat +2 moredrug
Likely dose
Vorinostat 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)
The University of Texas Health Science Center at San Antonio·interventional·Posted Dec 12, 2014·Updated Jan 5, 2024
In Brief
A Phase 2 clinical trial evaluating Vorinostat, Hydroxychloroquine, and 1 other intervention for Colorectal Cancer. Completed, enrolled 42 participants across 1 site.
Detailed Summary
This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartFeb 2015
Primary CompletionMar 2018
Study CompletionApr 2018
TodayJul 2026
First PostedDec 12, 2014
Enrollment StartFeb 11, 2015
Primary CompletionMar 7, 2018
Study CompletionApr 16, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.6 years ago
Interventions
Vorinostatdrug
400mg by mouth daily
Hydroxychloroquinedrug
600mg by mouth daily
Regorafenibdrug
160 mg by mouth daily